Osteosarcoma in Children Clinical Trial
— SARCOMASOfficial title:
Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas - Single-center Pilot Study of 32 Patients
| NCT number | NCT05107843 |
| Other study ID # | 7715 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | February 1, 2020 |
| Est. completion date | December 31, 2021 |
The aim of this pilot study is therefore to retrospectively measure the volume and percentage of necrosis on diagnostic MRI in T1 sequence and in parallel to study the expression of immunohistochemical markers of hypoxia (HIF-1α, CAIX , HIF-2α, pS6, phosphomTor, CD163 and CD68) on diagnostic biopsies of high-grade osteosarcomas from 2007 to 2018 in the Strasbourg center, focusing on the pediatric population. The investigators will systematically carry out a correlation analysis between these different parameters and with the clinical data of these same patients (response to chemotherapy, presence of metastases or not and overall and recurrence-free survival). This will eventually make it possible to highlight new prognostic markers at diagnosis.
| Status | Recruiting |
| Enrollment | 30 |
| Est. completion date | December 31, 2021 |
| Est. primary completion date | December 31, 2021 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 1 Year to 20 Years |
| Eligibility | Inclusion Criteria: - Subject = 20 years at diagnosis - Subject having been treated for osteosarcoma in the OS2006 protocol or treated according to - Supported at Strasbourg University Hospitals between 05/01/2007 and 10/31/2018 - Availability of its diagnostic tumor material stored in paraffin - having an MRI diagnostic evaluation comprising the injected T1 sequences necessary for the analysis of the volume / necrotic proportion. Exclusion Criteria: - Opposition of the patient (or his legal representatives if he is a minor) to participate in the study - Diagnosis other than osteosarcoma - Biological tissue from a patient who does not meet all the inclusion criteria - Patient under legal protection - Patient under guardianship or guardianship |
| Country | Name | City | State |
|---|---|---|---|
| France | Service Pédiatrie Onco-hématologie - Pédiatrie III - Hôpitaux Universitaires de Strasbourg | Strasbourg |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Strasbourg, France |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Retropsective study of pediatric osteosarcomas | Files analysed retrospectively from January 01, 2007 to December 31, 2018 will be examined] |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03628209 -
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT05794594 -
3D Printed Personalized Extendable Prosthesis
|
||
| Suspended |
NCT05558280 -
Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
|
Phase 2 | |
| Completed |
NCT04644913 -
Long-term Evaluation of the Quality of Life of Former Patients Treated With Orthopedic Surgery, With or Without Radiotherapy
|
||
| Active, not recruiting |
NCT04803877 -
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06341712 -
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
|
Phase 2 | |
| Terminated |
NCT03139318 -
Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity
|
N/A |